https://doi.org/10.55788/678374a1
The fungal pathogen A. fumigatus releases spores that may cause severe infections, especially in immunocompromised patients and several respiratory conditions like COPD, asthma, and cystic fibrosis [1,2]. Valentina Huang (Imperial College London, UK) pointed out that the increased use of antifungal agents in the last decades has led to a worldwide surge in azole-resistant Aspergillus infections [1]. To shed further light on the possible influence of air pollution on the emergence of this azole resistance, the researchers performed passaging of A. fumigatus in Sabouraud dextrose agar with and without diesel particles, using rising concentrations of itraconazole. Comparing susceptibility testing observed an appropriate correlation between the visual readings for MIC and absorbance results, thus the latter was used for further analyses. The MIC results of the passages were compared with the expected ranges of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) of the A. fumigatus strain ATCC204305. Apart from assessing MIC, genetic analyses were also performed.
Overall, a decreased susceptibility was determined with a 2 to 4 times higher itraconazole concentration needed for MIC. However, in the passages with diesel particles, the MIC for the azole was over 64-fold. In terms of genetics, the reverse transcription PCR analysis revealed a 2-fold expression of the fungal CYP51 protein in the presence of diesel compared with passages without. Results for drug efflux mediated by membrane transporters and Sanger sequencing for mutation on the CYP51A gene found no significant changes.
The authors expressed that these findings demonstrate the accelerated evolution of resistance against azole antifungal agents in the presence of diesel particles, but they also stated that further genetic analysis will be required to identify the underlying resistance mechanisms.
- Ito K, et al. Accelerated evolution of azole resistant Aspergillus fumigatus by diesel particles. Abstract 2182, ERS International Congress 2023, 9–13 September, Milan, Italy.
- Sen P, et al. Drug Target Insights. 2022;16:25-35.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Tacrolimus versus cyclosporin: Less lung graft dysfunction Next Article
Most severe asthma patients are candidates for biologic therapy on a global scale »
« Tacrolimus versus cyclosporin: Less lung graft dysfunction Next Article
Most severe asthma patients are candidates for biologic therapy on a global scale »
Table of Contents: ERS 2023
Featured articles
Letter from the Editor
Best of the Posters
sRAGE: A novel potential biomarker to assess the risk of acute respiratory events
Most severe asthma patients are candidates for biologic therapy on a global scale
Aspergillus infections: resistance to azole treatment increased in the presence of diesel particles
Asthma in 2023
Tapering from high-dose inhaled corticosteroids possible in most asthma patients treated with benralizumab
Tezepelumab therapy: hints toward a disease-modifying effect?
Digital inhaler programme improves asthma control also in the long term, but not long-term adherence
Respiratory health in children
Large infant study demonstrates the importance of a mature microbiome
Healthy maternal lifestyle during pregnancy reduces wheezing and rhinitis in infants
Mechanism of autophagy in a newborn responsible for deleterious effect of air pollutants
COPD: New Developments
Gabapentinoids increase risk of exacerbations in COPD
Future treatment of fatigue in COPD: 4 possible targets identified
Pulmonary Consequences of Long COVID
Women at higher risk of functional respiratory complaints following a COVID-19 infection
Elevated myeloid inflammation and complement activation present in various phenotypes of long COVID
Pulmonary Arterial Hypertension (PAH): Novel Developments
Encouraging long-term outcomes observed in the treatment of PAH with sotatercept
Chronic thromboembolic pulmonary hypertension: surgery entails encouraging long-term results
Women with pulmonary hypertension have better survival chances than men
Rare Diseases in 2023
Primary ciliary dyskinesia: Idrevloride shows promising results in phase 2 trial
Promising new agent as treatment for pulmonary fibrosis
Novel immunomodulator offers hope to reduce steroid dependency in sarcoidosis
Other Research of Interest
Tacrolimus versus cyclosporin: Less lung graft dysfunction
CPAP effective in reducing cardiovascular mortality in a practice study
Gefapixant curbs chronic cough independent of its duration
Related Articles
December 24, 2021
CPAP may not be effective in very old patients with OSA
November 7, 2018
IPF introduction and Pentraxin-2
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com